Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 92  

    Article Cited by others


Standard Operating Procedure for Prospective Individualised Dosimetry for [131] I-rituximab Radioimmunotherapy of Non-Hodgkin's Lymphoma

Calais Phillipe J, Turner J Harvey

Year : 2012| Volume: 11| Issue : 3 | Page no: 110-116

   This article has been cited by
1 Theranostic radiopharmaceuticals: established agents in current use
James R Ballinger
The British Journal of Radiology. 2018; : 20170969
[Pubmed]  [Google Scholar] [DOI]
2 A Pioneer Experience In Malaysia On In-house Radio-labelling of 131I-Rituximab In The Treatment Of Non-Hodgkinæs Lymphoma And A Case Report of High Dose 131I-Rituximab-BEAM Conditioning Autologous Transplant
Jew Win Kuan,Chiong Soon Law,Xiang Qi Wong,Ching Tiong Ko,Zool Hilmi Awang,Lee Ping Chew,Kian Meng Chang
Applied Radiation and Isotopes. 2016;
[Pubmed]  [Google Scholar] [DOI]
3 (Mis)use of 133Ba as a calibration surrogate for 131I in clinical activity calibrators
B.E. Zimmerman,D.E. Bergeron
Applied Radiation and Isotopes. 2015;
[Pubmed]  [Google Scholar] [DOI]


Read this article